CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

Home About What We Do Programs and Services CADTH Reimbursement Review Oxycodone / naloxone

Oxycodone / naloxone

Last Updated: November 30, 2010

Result type: Reports

Project Number: SR0219-000

Product Line: Reimbursement Review

Generic Name: Oxycodone / naloxone

Brand Name: Targin

Manufacturer: Purdue Pharma

Therapeutic Area: Pain, Moderate to severe and relief of opioid-induced constipation

Indications: Pain, Moderate to severe and relief of opioid-induced constipation

Submission Type: Initial

Project Status: Cancelled

Oxycodone / naloxone

Files